Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 194

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 194
---
 an aggregate 240,917shares of common stock, exercisable at $ 1.40per share, with such warrants expiring five yearsfrom issuance. In addition, the Company’s Chief Executive Officer, Dr. Anatoly Dritschilo, invested a total of $ 237,500in this financing round, in exchange for a $ 250,000convertible note.

On October 21, 2024, the Company issued an additional $ 231,579in senior secured convertible notes due in October 2025, with substantially similar terms as the October 14, 2024, issuance. The notes include a 5% original issue discount and the Company received $ 220,000in proceeds. The Company also issued warrants to the lenders to purchase an aggregate 88,544shares of common stock, exercisable at $ 1.49per share, with such warrants expiring five yearsfrom issuance. Upon completing this issuance, the Company closed the senior secured convertible note offering after receiving a total of $ 790,000in proceeds.

Alliance Global Partners

On October 31, 2024, the Company consummated a public offering of an aggregate of (i) 395,574shares of common stock and 2,555,246pre-funded warrants to purchase up to 2,555,246shares of common stock, and (ii) 2,950,820common stock purchase warrants to purchase up to 2,950,820shares of common stock. Each share of common stock, or a pre-funded warrant in lieu thereof, was sold together with an accompanying warrant to purchase one share of common stock. AGP served as lead underwriter along with Boustead as co-underwriter.

The public offering price for each share of common stock and one accompanying warrant was $ 1.525. The public offering price of each pre-funded warrant and one accompanying common warrant was $ 1.524, which equals the price at which one share of common stock and accompanying warrant was sold to the public in this offering, minus $ 0.001. The exercise price of each pre-funded warrant is $ 0.001per share. Each warrant offered in the offering is exercisable for one share of common stock and has an initial exercise price equal to $ 1.40. The Company received aggregate gross proceeds from the offering of approximately $ 4.5million, before deducting placement agents’ fees and other offering expenses.

| F-19 |

<div align='center'>